LYNPARZA Film-coated tablet Ref.[8404] Active ingredients: Olaparib

Source: European Medicines Agency (EU)  Revision Year: 2024  Publisher: AstraZeneca AB, SE-151 85 Södertälje, Sweden

Product name and form

Lynparza 100 mg film-coated tablets.

Lynparza 150 mg film-coated tablets.

Pharmaceutical Form

Film-coated tablet (tablet).

Lynparza 100 mg film-coated tablets: Yellow to dark yellow, oval, bi-convex tablet, debossed with ‘OP100’ on one side and plain on the other side.

Lynparza 150 mg film-coated tablets: Green to green/grey, oval, bi-convex tablet, debossed with ‘OP150’ on one side and plain on the other side.

Qualitative and quantitative composition

Lynparza 100 mg film-coated tablets: Each film-coated tablet contains 100 mg olaparib.

Lynparza 150 mg film-coated tablets: Each film-coated tablet contains 150 mg olaparib.

Excipient with known effect:

This medicinal product contains 0.24 mg sodium per 100 mg tablet and 0.35 mg sodium per 150 mg tablet.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Olaparib

Olaparib is a potent inhibitor of human poly (ADP-ribose) polymerase enzymes (PARP-1, PARP-2, and PARP-3), and has been shown to inhibit the growth of selected tumour cell lines in vitro and tumour growth in vivo either as a standalone treatment or in combination with established chemotherapies or new hormonal agents (NHA).

List of Excipients

Tablet core:

Copovidone
Silica, colloidal anhydrous
Mannitol
Sodium stearyl fumarate

Tablet coating:

Hypromellose
Macrogol 400
Titanium dioxide (E171)
Iron oxide yellow (E172)
Iron oxide black (E172) (150 mg tablets only)

Pack sizes and marketing

Alu/Alu non-perforated blister containing 8 film-coated tablets.

Pack sizes:

56 film-coated tablets (7 blisters).

Multipack containing 112 (2 packs of 56) film-coated tablets.

Not all pack sizes may be marketed.

Marketing authorization holder

AstraZeneca AB, SE-151 85 Södertälje, Sweden

Marketing authorization dates and numbers

EU/1/14/959/002 56 film-coated tablets (100 mg)
EU/1/14/959/003 112 film-coated tablets (2 packs of 56) (100 mg)
EU/1/14/959/004 56 film-coated tablets (150 mg)
EU/1/14/959/005 112 film-coated tablets (2 packs of 56) (150 mg)

Date of first authorisation: 16 December 2014
Date of latest renewal: 1 October 2019

Drugs

Drug Countries
LYNPARZA Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.